SETD2 histone modifier loss in aggressive GI stromal tumours.

Gut
Kie Kyon HuangPatrick Tan

Abstract

GI stromal tumours (GISTs) are clinically heterogenous exhibiting varying degrees of disease aggressiveness in individual patients. We sought to identify genetic alterations associated with high-risk GIST, explore their molecular consequences, and test their utility as prognostic markers. Exome sequencing of 18 GISTs was performed (9 patients with high-risk/metastatic and 5 patients with low/intermediate-risk), corresponding to 11 primary and 7 metastatic tumours. Candidate alterations were validated by prevalence screening in an independent patient cohort (n=120). Functional consequences of SETD2 mutations were investigated in primary tissues and cell lines. Transcriptomic profiles for 8 GISTs (4 SETD2 mutated, 4 SETD2 wild type) and DNA methylation profiles for 22 GISTs (10 SETD2 mutated, 12 SETD2 wild type) were analysed. Statistical associations between molecular, clinicopathological factors, and relapse-free survival were determined. High-risk GISTs harboured increased numbers of somatic mutations compared with low-risk GISTs (25.2 mutations/high-risk cases vs 6.8 mutations/low-risk cases; two sample t test p=3.1×10-5). Somatic alterations in the SETD2 histone modifier gene occurred in 3 out of 9 high-risk/metastatic cases...Continue Reading

References

May 10, 2002·The American Journal of Pathology·Christopher L CorlessMichael C Heinrich
May 11, 2002·Laboratory Investigation; a Journal of Technical Methods and Pathology·Takahiro TaguchiKazunari Yuri
Jul 3, 2002·Human Pathology·Christopher D M FletcherSharon W Weiss
Jan 11, 2003·Science·Michael C HeinrichJonathan A Fletcher
Dec 19, 2003·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Jerzy LasotaMarkku Miettinen
Sep 2, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Javier MartínUNKNOWN Spanish Group for Sarcoma Research
May 16, 2006·Gastroenterology·Johanna AnderssonBengt Nilsson
Dec 30, 2006·Seminars in Diagnostic Pathology·Markku Miettinen, Jerzy Lasota
Jan 2, 2007·The American Journal of Surgical Pathology·Abbas AgaimyArndt Hartmann
Jul 11, 2008·Genes, Chromosomes & Cancer·Narasimhan P AgaramCristina R Antonescu
Feb 26, 2009·Nature Genetics·Robert J Sims, Danny Reinberg
Mar 24, 2009·Lancet·Ronald P DematteoUNKNOWN American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team
Mar 31, 2009·Nature Biotechnology·Madeleine P BallGeorge M Church
May 20, 2009·Bioinformatics·Heng Li, Richard Durbin
Jun 10, 2009·Bioinformatics·Heng LiUNKNOWN 1000 Genome Project Data Processing Subgroup
Jun 11, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Salvatore RomeoUNKNOWN European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
May 18, 2010·Journal of the National Comprehensive Cancer Network : JNCCN·George D DemetriJeffrey D Wayne
Jun 16, 2010·The Journal of Biological Chemistry·Arunkumar DhayalanAlbert Jeltsch
Mar 29, 2011·Nature·Jason ErnstBradley E Bernstein
Apr 30, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A WozniakUNKNOWN Polish Clinical GIST Registry
Nov 18, 2011·Nature Reviews. Cancer·Christopher L CorlessMichael C Heinrich
Jan 20, 2012·Cancer Research·Takeshi NiinumaYasuhisa Shinomura
Jan 28, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Claudia MirandaMilo Frattini
Mar 9, 2012·The New England Journal of Medicine·Marco GerlingerCharles Swanton
Mar 29, 2012·JAMA : the Journal of the American Medical Association·Heikki JoensuuPeter Reichardt
Jul 5, 2012·Genome Research·Nathan D DeesLi Ding
Jan 18, 2013·Nucleic Acids Research·Sílvia CarvalhoSérgio Fernandes de Almeida
Apr 27, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·A Ari HakimiUNKNOWN ccRCC Cancer Genome Atlas (KIRC TCGA) Research Network investigators

❮ Previous
Next ❯

Citations

Dec 9, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Margaret von Mehren, Heikki Joensuu
Oct 5, 2019·Nature Structural & Molecular Biology·Dylan Husmann, Or Gozani
Oct 24, 2019·American Journal of Medical Genetics. Part C, Seminars in Medical Genetics·Pauline MarzinValérie Cormier-Daire
Aug 22, 2017·The Journal of Clinical Investigation·Huairui YuanJun Qin
May 28, 2019·Veterinary Sciences·Kelly M MakielskiJaime F Modiano
Feb 6, 2017·Cold Spring Harbor Perspectives in Medicine·Catherine C Fahey, Ian J Davis
Oct 2, 2019·Laboratory Investigation; a Journal of Technical Methods and Pathology·Peifeng LiZhe Wang
Oct 23, 2019·Proceedings of the National Academy of Sciences of the United States of America·Yuzhi PangYuexiang Wang
Jul 14, 2018·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·X Liu, K-M Chu
Feb 7, 2020·Cell & Bioscience·Yaping Huang, Guo-Min Li
Nov 12, 2016·Proceedings of the National Academy of Sciences of the United States of America·Yoshie YoshikawaMichele Carbone
Apr 13, 2021·Breast Cancer Research and Treatment·Julia Y TsangGary M Tse
Nov 23, 2021·Frontiers in Cell and Developmental Biology·Yuyang FengZhaohui Huang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics and Chromatin (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin and its role in cancer epigenetics please follow this feed to learn more.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Stem Cells in Glioblastoma

Glioblastoma is the most common and aggressive type of brain tumor. It contains a population of tumor initiating stem cell-like cells known as cancer stem cells. Investigations are ongoing into these cancer stem cells found in these solid tumors which are highly resistance to treatment. Here is the latest research on cancer stem cells in glioblastoma.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cancer Epigenetics Chromatin Complexes (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin complexes and their role in cancer epigenetics.